Kalaris Therapeutics, Inc. (KLRS)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$2.97−$0.1000 (−3.26%) on the dayAs of the close; data may be delayed.
KLRS price, last 12 months
Key stats
- Previous close
- $3.07
- Open
- $3.02
- Day range
- $2.91 – $3.09
- 52-week range
- $2.91 – $11.88
- Volume
- 45.2K
- Avg volume (20 days)
- 64.1K
- Market cap
- $69.5M
Performance
1W−7.2%
1M−27.2%
3M−31.3%
6M−49.0%
YTD−64.8%
1Y−34.4%
vs S&P 500, 1Y−51.2 pts
Technicals and fundamentals
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $69.5M